LTP TECHNOLOGY Trademark

Trademark Overview

On Friday, March 29, 2019, a trademark application was filed for LTP TECHNOLOGY with the United States Patent and Trademark Office. The USPTO has given the LTP TECHNOLOGY trademark a serial number of 88363841. The federal status of this trademark filing is REGISTERED as of Tuesday, June 21, 2022. This trademark is owned by Ligand Pharmaceuticals Incorporated. The LTP TECHNOLOGY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development of a process to deliver organ specific pharmaceutical preparations
ltp technology

General Information

Serial Number88363841
Word MarkLTP TECHNOLOGY
Filing DateFriday, March 29, 2019
Status700 - REGISTERED
Status DateTuesday, June 21, 2022
Registration Number6768469
Registration DateTuesday, June 21, 2022
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, July 30, 2019

Trademark Statements

Description of MarkThe mark consists of the term "LTP" above the word "TECHNOLOGY" in a smaller font, with a design comprised of several intersecting and connecting lines to the right of the term "LTP" and forming the shape of a liver.
Pseudo MarkLIGAND PHARMACEUTICALS TECHNOLOGY
Indication of Colors claimedColor is not claimed as a feature of the mark.
NOT AVAILABLE"TECHNOLOGY"
Goods and ServicesPharmaceutical research and development of a process to deliver organ specific pharmaceutical preparations

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, April 18, 2019
Primary Code042
First Use Anywhere DateFriday, November 30, 2018
First Use In Commerce DateFriday, November 30, 2018

Trademark Owner History

Party NameLigand Pharmaceuticals Incorporated
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJupiter, FL 33458
Party NameLigand Pharmaceuticals Incorporated
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressEmeryville, CA 94608
Party NameLigand Pharmaceuticals Incorporated
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Friday, June 21, 2019ASSIGNED TO LIE
Wednesday, July 10, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 30, 2019PUBLISHED FOR OPPOSITION
Tuesday, April 2, 2019NEW APPLICATION ENTERED
Thursday, April 18, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 19, 2019NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, June 10, 2019ASSIGNED TO EXAMINER
Tuesday, June 11, 2019EXAMINERS AMENDMENT -WRITTEN
Tuesday, June 11, 2019EXAMINERS AMENDMENT E-MAILED
Tuesday, June 11, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, June 11, 2019EXAMINER'S AMENDMENT ENTERED
Tuesday, June 11, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 10, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, July 30, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 24, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 10, 2020SOU EXTENSION 1 FILED
Tuesday, March 10, 2020SOU EXTENSION 1 GRANTED
Wednesday, September 16, 2020SOU TEAS EXTENSION RECEIVED
Thursday, March 12, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 16, 2020SOU EXTENSION 2 FILED
Wednesday, September 16, 2020SOU EXTENSION 2 GRANTED
Tuesday, March 2, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, March 2, 2021SOU EXTENSION 3 FILED
Tuesday, March 2, 2021SOU EXTENSION 3 GRANTED
Friday, September 18, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 21, 2021TEAS STATEMENT OF USE RECEIVED
Tuesday, September 21, 2021USE AMENDMENT FILED
Thursday, March 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 5, 2021STATEMENT OF USE PROCESSING COMPLETE
Monday, October 4, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 3, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 6, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 26, 2021SU - NON-FINAL ACTION - WRITTEN
Tuesday, October 26, 2021NON-FINAL ACTION E-MAILED
Tuesday, October 26, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, January 6, 2022ASSIGNED TO LIE
Thursday, January 6, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 27, 2022FINAL REFUSAL E-MAILED
Thursday, January 27, 2022SU - FINAL REFUSAL - WRITTEN
Thursday, January 27, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, May 18, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, May 19, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 21, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, August 26, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, August 26, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, August 26, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, August 26, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, August 26, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 21, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

technology pharmaceutical specific preparations organ process research development deliver